Biomarkers

Serum levels of miR-940, miR-451a, miR-16-5p and miR-17-3p could help predict response to Herceptin trastuzumab in HER2 (EGFR2; ErbB2; neu)-positive metastatic breast cancer patients. In 283 HER2-positive metastatic breast cancer patients receiving Herceptin, a risk score calculated from the serum levels of the four miRNAs was associated with poor overall survival and progression-free survival. Next steps include a prospective clinical study to validate the findings and using them to develop a prognostic test...